Accessibility Menu
Shanghai Pharmaceuticals logo

Shanghai Pharmaceuticals(OTC) SHPMY

Market Cap$1.33BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)-21%
5 Year-11%
1 Year-5%
1 Month+2%
$7.24
+0.00%
+0.00Today
Shanghai Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 7.242026-08-31
Shanghai Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.97%USD 7.392026-08-21
1 month+2.22%USD 7.082026-07-28
3 month-1.28%USD 7.332026-05-27
Year to date-7.89%USD 7.862025-12-30
1 year-5.24%USD 7.642025-08-22
3 year-2.49%USD 7.422023-09-01
5 year-10.9%USD 8.132021-09-01
Since inception-21.14%USD 9.182014-02-19

Shanghai Pharmaceuticals Financials at a Glance

Market Cap

$1.33BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥288.87B

Net Income (TTM)

CN¥4.76B

EPS (TTM)

$0.93

P/E Ratio

7.79

Dividend

$0.34

Beta (Volatility)

0.14 (Low)

Price

$7.24

Volume

340

Open

$7.22

Previous Close

$7.24

Daily Range

$7.22 - $7.24

52-Week Range

$7.04 - $8.32

Estimated Earnings Date

Apr 27, 2026

SHPMY News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Shanghai Pharmaceuticals

Shanghai Pharmaceuticals Holding Co., Ltd. is a leading investment holding enterprise in China's pharmaceutical and healthcare sectors. The company engages in a comprehensive range of activities, including drug research and development, manufacturing, distribution, and retail sales of various health-related products.

Products and Services
  • Over 700 pharmaceutical formulations, including chemical compounds and traditional Chinese remedies
  • Comprehensive pharmaceutical supply chain management services
  • Extensive retail network with approximately 2,000 chain pharmacies across 24 provinces
Growth Outlook
  • Revenue growth of 9.8% year-over-year in the latest quarter
  • Strong demand for healthcare products amid increasing health awareness
  • Expansion plans for online drug commerce platform to enhance market reach
Financial Highlights
  • Recent quarterly revenue of 75.26 billion CNY, reflecting robust sales performance
  • Trailing twelve months (TTM) net income margin of 2.02%, indicating profitability
  • Dividend yield of 2.81%, providing attractive returns to shareholders
Shanghai Pharmaceuticals Holding Co., Ltd. operates through four main divisions: Production, Distribution, Retail, and Other services. The company’s diverse product offerings cater to a wide range of medical conditions, including oncology, cardiovascular issues, and respiratory conditions. With a significant retail presence and a strong online platform, the company is well-positioned to capitalize on the growing demand for healthcare products in China. Recent financial performance indicates a solid revenue trajectory, supported by strategic growth initiatives and a commitment to enhancing service offerings. The company's focus on supply chain management and retail expansion further strengthens its competitive position in the market.
AI Generated • Aug 12, 2026

Industry

Healthcare Providers and Services

Sector

Health Care

Employees

49,608

CEO

Da Wei Liu

Website

www.sphchina.com

Headquarters

Shanghai, SH 200020, CN

SHPMY Financials

Key Financial Metrics (TTM)

Gross Margin

10.79%

Operating Margin

2.78%

Net Income Margin

1.65%

Return on Equity

6.21%

Return on Capital

7.93%

Return on Assets

1.98%

Earnings Yield

12.84%

Dividend Yield

4.73%

Payout Ratio

61.50%

Stock Overview

Market Cap

$1.33BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

183.81M

Volume

340

Avg. Volume

144.469

Financials (TTM)

Gross Profit

CN¥31.22B

Operating Income

CN¥8.04B

EBITDA

CN¥10.45B

Operating Cash Flow

CN¥9.83B

Capital Expenditure

-CN¥2.25B

Free Cash Flow

CN¥7.58B

Cash & ST Invst.

CN¥46.01B

Total Debt

CN¥65.96B

Shanghai Pharmaceuticals Performance Analysis

Shanghai Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 34,375,991,0662.9%
20232023-12-31CNY 36,634,570,8966.6%
20242024-12-31CNY 38,177,833,0814.2%
20252025-12-31CNY 39,376,745,7863.1%
Shanghai Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-303.2%
Q42025-12-31-6.3%
Q12026-03-319.9%
Q22026-06-30-4.3%
Shanghai Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY 1.20-13.8%
20232023-12-31CNY 0.72-40.0%
20242024-12-31CNY 0.8518.9%
20252025-12-31CNY 1.0725.7%
Shanghai Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-77.4%
Q42025-12-31-21.1%
Q12026-03-31153.3%
Q22026-06-3047.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥72.00B

+1.7%

Gross Profit

CN¥7.68B

+0.1%

Gross Margin

10.67%

N/A

Market Cap

$1.33BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$26.83K

N/A

Employees

49,608

N/A

Net Income

CN¥2.08B

-33.4%

EBITDA

CN¥3.31B

+20.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥46.01B

-3.1%

Total Debt

CN¥65.96B

+27.5%

Accounts Receivable

CN¥97.22B

+5.4%

Inventory

CN¥42.70B

+4.4%

Long Term Debt

CN¥4.75B

-22.2%

Short Term Debt

CN¥61.21B

+34.2%

Return on Assets

1.98%

N/A

Return on Invested Capital

7.98%

N/A

Free Cash Flow

CN¥5.13B

+83.4%

Operating Cash Flow

CN¥5.49B

+71.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
DSRLFDiaSorin S.p.A.
$86.00+0.00%
CNVVYConvaTec Group Plc
$12.47-1.86%
SHTDYSinopharm Group Co. Ltd.
$9.83+1.02%
GZPHFGuangzhou Baiyunshan Pharmaceutical Holdings Company Limited
$2.34+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$10.38+0.11%
NVDANvidia
$228.45+0.02%
SPCXSpace Exploration Technologies
$149.74+0.06%
BITOProShares Trust - ProShares Bitcoin ETF
$11.01+0.06%

Questions About SHPMY

What is the current price of Shanghai Pharmaceuticals?

Shanghai Pharmaceuticals is trading at $7.24 per share.

What is the 52-week range for Shanghai Pharmaceuticals?

Over the past 52 weeks, Shanghai Pharmaceuticals has traded between $7.04 and $8.32.

How much debt does Shanghai Pharmaceuticals have?

As of the most recent reporting period, Shanghai Pharmaceuticals reported total debt of CN¥9.72B.

How much cash does Shanghai Pharmaceuticals have on hand?

Shanghai Pharmaceuticals reported CN¥5.13B in cash and cash equivalents in its most recent financial results.

What is Shanghai Pharmaceuticals’s dividend yield?

Shanghai Pharmaceuticals currently has a dividend yield of 4.73%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services